[go: up one dir, main page]

TR200201192T1 - Kanser terapi maddelerinin kuvvetlendirilmesine yönelik metod ve terkipler - Google Patents

Kanser terapi maddelerinin kuvvetlendirilmesine yönelik metod ve terkipler

Info

Publication number
TR200201192T1
TR200201192T1 TR2002/01192T TR200201192T TR200201192T1 TR 200201192 T1 TR200201192 T1 TR 200201192T1 TR 2002/01192 T TR2002/01192 T TR 2002/01192T TR 200201192 T TR200201192 T TR 200201192T TR 200201192 T1 TR200201192 T1 TR 200201192T1
Authority
TR
Turkey
Prior art keywords
compositions
methods
cancer therapy
therapy agents
strengthening
Prior art date
Application number
TR2002/01192T
Other languages
English (en)
Inventor
J. Jariwalla Raxit
Original Assignee
Oxycal Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxycal Laboratories, Inc. filed Critical Oxycal Laboratories, Inc.
Publication of TR200201192T1 publication Critical patent/TR200201192T1/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Kanser kemoterapi maddelerinin etkisi mineral askorbatlar, Vitamin C metabolitleri ve/veya Vitamin C'den türetilmis furanon, örnegin 4-hidroksi-5-metil-3(2H)-furanon ile birlestirilmek suretiyle daha da kuvvetlendirilebilmektedir.
TR2002/01192T 2000-09-01 2001-08-24 Kanser terapi maddelerinin kuvvetlendirilmesine yönelik metod ve terkipler TR200201192T1 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/654,377 US6468980B1 (en) 2000-09-01 2000-09-01 Methods and compositions for potentiating cancer chemotherapeutic agents

Publications (1)

Publication Number Publication Date
TR200201192T1 true TR200201192T1 (tr) 2003-05-21

Family

ID=24624611

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/01192T TR200201192T1 (tr) 2000-09-01 2001-08-24 Kanser terapi maddelerinin kuvvetlendirilmesine yönelik metod ve terkipler

Country Status (15)

Country Link
US (1) US6468980B1 (tr)
EP (1) EP1286674B1 (tr)
JP (1) JP2004508335A (tr)
KR (1) KR20030019297A (tr)
AT (1) ATE400267T1 (tr)
AU (1) AU8525401A (tr)
CA (1) CA2389602A1 (tr)
CY (1) CY1108787T1 (tr)
DE (1) DE60134740D1 (tr)
DK (1) DK1286674T3 (tr)
ES (1) ES2309085T3 (tr)
MX (1) MXPA02004327A (tr)
PT (1) PT1286674E (tr)
TR (1) TR200201192T1 (tr)
WO (1) WO2002020023A1 (tr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878744B2 (en) * 1999-02-05 2005-04-12 Oxycal Laboratories, Inc. Vitamin C compositions
CN1197561C (zh) * 2001-07-03 2005-04-20 北京巨能亚太生命科学研究中心 L－苏糖酸钙在制备预防或治疗损及软骨的疾病的药物中的用途
US8414871B2 (en) * 2002-05-15 2013-04-09 Rutgers, The State University Of New Jersey Controlled releases of actives in skin
ATE444063T1 (de) 2003-08-13 2009-10-15 Ester C Company Verfahren zur linderung von umweltbedingtem stress durch oxidationsmittel und regulierung vorteilhafter gene
KR101998246B1 (ko) * 2018-08-22 2019-07-10 주식회사 메타파인즈 금속이온에 결합된 이온화합물을 포함하는 암 치료용 약학 조성물
TR2022000209A2 (tr) 2022-01-07 2022-02-21 Oezge Gueven Ozoni̇ze c-vi̇tami̇ni̇ i̇çeren bi̇r anti̇-kanser i̇laci

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0249632A4 (en) * 1985-12-05 1988-06-20 American Biotechnology ATHRACYCLINE TYPE OF ANTITUARY WITH L-ASCORBIC ACID.
GB8810173D0 (en) * 1988-04-29 1988-06-02 Norsk Hydro As Pharmaceutical compositions with anti-cancer activity & method for treatment of cancer
WO1990012571A1 (en) * 1989-04-07 1990-11-01 Oxycal Laboratories, Inc. Compositions and methods for administering vitamin c
JPH08291075A (ja) * 1995-04-20 1996-11-05 Showa Denko Kk 癌転移阻害剤
EP0875246A1 (en) * 1997-04-04 1998-11-04 Showa Denko Kabushiki Kaisha Pharmaceutical preparation of ascorbic acid derivatives for medical treatment of cancer
CA2275420C (en) * 1998-02-06 2007-05-29 Oxycal Laboratories, Inc. Stable liquid mineral ascorbate compositions and methods of manufacture and use
EP1124550B9 (en) * 1999-08-30 2008-11-05 The Ester C Company Uses and compositions for selective cancer chemotherapy

Also Published As

Publication number Publication date
KR20030019297A (ko) 2003-03-06
EP1286674B1 (en) 2008-07-09
CY1108787T1 (el) 2014-04-09
DK1286674T3 (da) 2008-11-03
EP1286674A1 (en) 2003-03-05
CA2389602A1 (en) 2002-03-14
DE60134740D1 (de) 2008-08-21
ATE400267T1 (de) 2008-07-15
PT1286674E (pt) 2008-08-21
EP1286674A4 (en) 2005-12-21
AU8525401A (en) 2002-03-22
ES2309085T3 (es) 2008-12-16
MXPA02004327A (es) 2002-11-07
WO2002020023A1 (en) 2002-03-14
JP2004508335A (ja) 2004-03-18
US6468980B1 (en) 2002-10-22

Similar Documents

Publication Publication Date Title
MXPA03007140A (es) Derivados de carbolina.
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
DE60106954D1 (de) Resorcin-derivate
DE60216233D1 (en) Carbolinderivate
BR9912327A (pt) Inibidores da uroquinase
CY1108787T1 (el) Συνθεση για ενισχυση χημειοθεραπευτικων παραγοντων καρκινου
TR200201245T2 (tr) Kanser tedavisi için onkolitik kombinasyonlar.
EA200200808A1 (ru) Модифицированные цитокины, предназначенные для применения в терапии рака
TR200101693T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
BG105964A (en) C(10) carbonate substituted taxanes and their use as antitumor agents
BR0111785A (pt) Composições e métodos para tratamento de candidìase
TR200302193T4 (tr) Kombinasyon kemoterapisi.
AU4558201A (en) Taxane anticancer agents
ATE401325T1 (de) C10-carbamoyloxysubstituierte taxane als antitumormittel
ATE392422T1 (de) C7-carbamoyloxysubstituierte taxane als antitumormittel
DE60136706D1 (de) Ycin-acryloyl derivate und antimetabolische mitteln
BR0113202A (pt) Compostos de trioxepano
DE60003189D1 (de) Synergistische zusammensetzung, die daunorubicin derivate und antimetabolite enthält